Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gloucester Pharmaceuticals Inc.

Division of Celgene Corp.
www.gloucesterpharma.com

Latest From Gloucester Pharmaceuticals Inc.

Celgene's Partnered Pipeline Delivers Successes And Setbacks

Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.

Deals Business Strategies

For Its Latest Epigenetics Deal, Celgene Takes Option To Buy Acetylon

A $100 million, non-dilutive investment will keep Acetylon off the market, giving Celgene the right to buy it for a minimum of $500 million up-front within a pre-determined time window. For now, Acetylon retains all rights to its pipeline, including Phase Ib multiple myeloma drug ACY-1215.

BioPharmaceutical United States

NewLink Genetics appoints Wiley business development VP

Iowa-based NewLink Genetics, a company developing novel immunotherapeutic products to improve treatment options for cancer patients, has named Brian Wiley as vice president of business development.

Cancer

Former Yaupon Therapeutics Raises $15 Million In Debt To Prepare To Commercialize Its First Product

Now called Ceptaris, the company is awaiting FDA approval of mechlorethamine gel, a topical formulation of a cytotoxin, for early-stage CTCL.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Celgene Corp.
  • Senior Management
  • Alan Colowick, CEO
    Jean C Nichols, PhD, Pres. & COO
  • Contact Info
  • Gloucester Pharmaceuticals Inc.
    Phone: (617) 583-1300
    One Broadway
    14th Fl.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register